- Home
- DMAC vs NAUT Comparison
DMAC vs NAUT Comparison
Compare DMAC & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- NAUT
- Stock Information
- Founded
- DMAC 2000
- NAUT 2016
- Country
- DMAC United States
- NAUT United States
- Employees
- DMAC N/A
- NAUT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- DMAC Health Care
- NAUT Industrials
- Exchange
- DMAC Nasdaq
- NAUT Nasdaq
- Market Cap
- DMAC 267.7M
- NAUT 214.7M
- IPO Year
- DMAC N/A
- NAUT N/A
- Fundamental
- Price
- DMAC $6.51
- NAUT $1.54
- Analyst Decision
- DMAC Strong Buy
- NAUT Hold
- Analyst Count
- DMAC 3
- NAUT 3
- Target Price
- DMAC $7.00
- NAUT $3.58
- AVG Volume (30 Days)
- DMAC 81.8K
- NAUT 95.6K
- Earning Date
- DMAC 03-18-2025
- NAUT 02-27-2025
- Dividend Yield
- DMAC N/A
- NAUT N/A
- EPS Growth
- DMAC N/A
- NAUT N/A
- EPS
- DMAC N/A
- NAUT N/A
- Revenue
- DMAC N/A
- NAUT N/A
- Revenue This Year
- DMAC N/A
- NAUT N/A
- Revenue Next Year
- DMAC N/A
- NAUT N/A
- P/E Ratio
- DMAC N/A
- NAUT N/A
- Revenue Growth
- DMAC N/A
- NAUT N/A
- 52 Week Low
- DMAC $2.14
- NAUT $1.53
- 52 Week High
- DMAC $6.82
- NAUT $3.09
- Technical
- Relative Strength Index (RSI)
- DMAC 62.22
- NAUT 34.99
- Support Level
- DMAC $5.75
- NAUT $1.68
- Resistance Level
- DMAC $6.82
- NAUT $1.76
- Average True Range (ATR)
- DMAC 0.30
- NAUT 0.10
- MACD
- DMAC 0.02
- NAUT -0.01
- Stochastic Oscillator
- DMAC 74.48
- NAUT 3.70
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.